title: Conjugates of synthetic lymphocyte-activating lipopeptides with segments from HIV proteins induce protein-specific antibody formation.
abstract: Lipopeptide analogues of bacterial lipoprotein activate macrophages and B lymphocytes. The products formed by coupling these lipopeptides to low molecular mass antigens can be used to induce antigen-specific antibodies in mice. In the present work, it is shown that HIV-1 gp160-derived synthetic oligopeptides coupled to the synthetic lipodipeptide N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteinyl-s eryl- serine (P3CSS) induce peptide-specific antibodies in mice without adding further adjuvants. Depending on the peptides applied, the conjugates exhibited different lymphocyte stimulatory activity, immunoglobulin isotype patterns, and boost reactions; lipopeptide conjugates inducing a pronounced secondary immune response are considered to possess both B- and T-cell epitopes. Antibodies induced by the lipopeptide-HIV-1-peptide conjugates were also reactive against the recombinant gp160 of HIV-1.
authors.affiliation: Institut für Immunbiologie der Universität Freiburg.
authors.forename: M
authors.initials: M
authors.lastname: Loleit
authors.forename: W
authors.initials: W
authors.lastname: Tröger
authors.forename: K H
authors.initials: KH
authors.lastname: Wiesmüller
authors.forename: G
authors.initials: G
authors.lastname: Jung
authors.forename: M
authors.initials: M
authors.lastname: Strecker
authors.forename: W G
authors.initials: WG
authors.lastname: Bessler
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D000918:Antibody Specificity; D001402:B-Lymphocytes / Q000276:immunology; D004151:Dipeptides / Q000378:metabolism / Q000494:pharmacology; D000939:Epitopes / Q000276:immunology; D015686:Gene Products, env / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D015683:Gene Products, gag / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D015488:HIV Antigens / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D019302:HIV Envelope Protein gp160; D008074:Lipoproteins / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D010455:Peptides / Q000276:immunology / Q000494:pharmacology*; D011498:Protein Precursors / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000276:immunology; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus
chemical_list: D004151:Dipeptides; D000939:Epitopes; D015686:Gene Products, env; D015683:Gene Products, gag; D015488:HIV Antigens; D019302:HIV Envelope Protein gp160; D008074:Lipoproteins; D010455:Peptides; D011498:Protein Precursors; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus; C054858:p17 protein, Human Immunodeficiency Virus Type 1; C047210:2,3-bis-(palmitoyloxy)-2-propyl-N-palmitoyl-cysteinylserine; C061893:N-palmitoyl-5,6-dipalmitoyl-S-glycerylcysteinyl-seryl-serine